Market Place
Sourcing Support
Ilumya Effective In Moderate-To-Severe Nail Psoriasis At AAD 2025
07 Mar 2025 //
PR NEWSWIRE
Almirall To Present New Psoriasis Atopic Dermatitis Data
23 Sep 2024 //
BUSINESSWIRE
Sun Pharma`s Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.
04 Apr 2024 //
FDA
Sun Pharma specialty drug Tildrakizumab makes it to China`s reimbursement list
13 Dec 2023 //
ECONOMIC TIMES
Almirall`s Ilumetri® (tildrakizumab) Significantly Improves Wellbeing
11 Oct 2023 //
BUSINESSWIRE
Almirall: Ilumetri improved the wellbeing of patients with plaque psoriasis
07 Jul 2023 //
BUSINESSWIRE
Sun Pharma gets China NMPA approval for ILUMETRI
30 May 2023 //
EXPRESSPHARMA
Sun`s Biologic Ilumya (Tildrakizumab) Receives Approval in the U.S.
19 Dec 2022 //
FDA
Sun Pharma to Present Data Abstracts for ILUMYA in Plaque Psoriasis at 2022 AAD
24 Mar 2022 //
PRNEWSWIRE
Sun Pharma`s (Pr)ILUMYA now available for plaque psoriasis in Canada
28 Oct 2021 //
BIOSPACE
Sun brings Ilumya patient stories to light with patient chats
23 Aug 2021 //
FIERCE PHARMA
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA®
02 Nov 2020 //
PRNEWSWIRE
Sun Pharma drug delivers sustained skin clearance in psoriasis trial
02 Nov 2020 //
CLINICALTRIALSARENA
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA®
29 Oct 2020 //
PRNEWSWIRE
AnaptysBio Reports Positive Topline Data from GALLOP Ph 2 Trial of Imsidolimab
13 Oct 2020 //
GLOBENEWSWIRE
Almirall announces approval of the reimbursed price for Ilumetri®
13 Oct 2020 //
PRNEWSWIRE
Sun Pharma Announces the Launch of ILUMYA® (tildrakizumab) for Treatment of Plaque Psoriasis in Japan
22 Sep 2020 //
PRESS RELEASE
Sun Pharma gets nod from Japan govt for plaque psoriasis treatment drug
29 Jun 2020 //
MONEYCONTROL
Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA™
15 Jun 2020 //
PRESS RELEASE
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA™
12 Jun 2020 //
PRNEWSWIRE
Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts
10 Jun 2020 //
PRNEWSWIRE
SMC rejects Orkambi, accepts four medicines
13 Aug 2019 //
PHARMA TIMES
Sun Pharma announces regulatory filing of Tildrakizumab in Japan
01 Aug 2019 //
BIOSPECTRUMASIA
Sun Pharma seeks manufacturing & marketing approval for tildrakizumab from Japan
31 Jul 2019 //
PHARMABIZ
RCGP warns new PM that we ‘cannot risk no-deal disruption’
31 Jul 2019 //
PHARMATIMES
Top Indian drugmakers expand in China as policy changes trigger opportunity
18 Jul 2019 //
FIERCE PHARMA
Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA
19 Jun 2019 //
PR NEWSWIRE
FDA greenlights Herceptin copycat from Amgen, Allergan
18 Jun 2019 //
ENDPTS
Sun Pharma Announces ILUMYA™ (tildrakizumab-asmn) in US for Plaque Psoriasis
23 Oct 2018 //
PR NEWSWIRE
Almirall SA`s Ilumetri (tildrakizumab) Receives Approval in EU
09 Oct 2018 //
EMA
Sun Pharma jumps 2% as partner gets drug nod
19 Sep 2018 //
ECONOMIC TIMES
Sun Pharma gains 2% after receiving approval from European Commission
18 Sep 2018 //
INDIA INFOLINE
Meeting highlights from the CHMP 23-26 July 2018
31 Jul 2018 //
EMA
